Allarity Therapeutics Reports Third Quarter 2024 Financial Results and Provides Recent Operational Highlights
Cash balance at $18.5 million Strengthened leadership team with new members driving stenoparib development NASDAQ compliance regained Boston (November 14, 2024)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical- …